凝血的

The structures, functions and anticoagulant mechanisms of anticoagulation factors ACF I and ACF II from the venom of Agkistrodon acutus have been investigated. Both ACF I and ACF II form a 1:1 complex with activated coagulation factor X in a Calcium ion-dependent fashion which prevents the interaction of FXa with other proteins in the coagulation process, therefore ACF I and ACF II have marked anticoagulant activity.

中文摘要：对尖吻蝮蛇毒中抗凝血因子ACF I和ACF II的结构、功能和抗凝机理等进行了深入研究，发现ACF I和ACF II均与活化凝血因子X结合成1：1的复合物，从而阻止了FXa进一步参加凝血过程中反应，因而具有显著的抗凝血活性。

Both ACF I and ACF II form a 1:1 complex with activated coagulation factor X in a Calcium ion-dependent fashion which prevents the interaction of FXa with other proteins in the coagulation process, therefore ACF I and ACF II have marked anticoagulant activity.

对尖吻蝮蛇毒中抗凝血因子ACF I和ACF II的结构、功能和抗凝机理等进行了深入研究，发现ACF I和ACF II均与活化凝血因子X结合成1：1的复合物，从而阻止了FXa进一步参加凝血过程中反应，因而具有显著的抗凝血活性。

By measuring changes of Plasma levels of GMP-140, GP lib/III a and D-dimer in patients with OSAS before and after the institution of nasal continuous positive airway pressure, we want to study whether plate activation and enhance coagulability, fibrinolytic activation occur and play a role in prevalence ofcerebrovascular and cardiovascular events in patients with OSAS and the association with hypoxemia, if so, whether therapy with nCPAP alters this effect.

我们通过检测OSAS患者血浆α-颗粒膜蛋白(GMP-140)、血小板膜糖蛋白Ⅱb／Ⅲa和D-二聚体的变化，了解OSAS患者体内是否也存在血小板活化、凝血激活和继发纤溶亢进及其与低氧血症的关系，进一步从分子生物学角度探讨血小板活化、凝血激活和继发纤溶亢进在OSAS发生发展中的作用及经鼻持续气道正压通气对其影响。

The aim of this study was to explore the potential relationship between the enhancement of instant hemostatic function in vivo of cryopreserved platelets and its procoagulative related molecule activities. The ability of platelet binding factor Ⅴ, density of GPIb-Ⅸ-Ⅴ(CD42a) at platelet member surface were detected by flow cytometry, the clotting time induced by activated platelets were evaluated by coagulometer and platelet count, MPⅤ and PDW were measured by hemocytometer before and after fresh platelets were cryopreserved.

为了探索血小板冰冻保存后膜表面促凝血活性相关分子变化与冰冻血小板体内即刻止凝血功能增强之间的可能联系，用流式细胞术检测了新鲜血小板冰冻保存前后Ⅴ因子结合能力、血小板膜表面GPIb-Ⅸ-Ⅴ分子(CD42a)密度，用血凝仪测定激活血小板诱导血浆凝固时间变化，用血细胞计数仪测定血小板计数、MPⅤ和PDW。

The authors consider that is abnormal coagulation in steroid-i nduced necrosis of femoral head,and it might be caused by exogen ous steroid damaged the vascular endotheliod of those intraosseous and extraosse ous;or the platelet and other coagulable active mass be actived by immunocomp lex deposited in the vascular wall.

认为激素性股骨头缺血坏死发病过程中，系统存在异常的凝血状态。这种异常的凝血状态很可能是外源性激素造成了骨内外血管内皮损害或免疫复合物沉积在血管壁，进一步激活了血小板及其它凝血活性物质后引起的。

Objective To explore the relationship between incidence of hemorrhage in patients with leukemia and changes of the markers of coagulation, anticoagulation and fibrinolysis.

目的 观察白血病病人凝血、抗凝及纤溶指标的变化，以探讨凝血系统的变化与白血病并发出血的关系。

Monitoring of therapeutic doses of UFH can be achieved using the activated partial thromboplastin time and activated cloting time.

普通的抗凝治疗可通过活化部分凝血活酶时间及活化凝血时间来监测。

The in vitro anticoagulation activity of the sample was evaluated by activated partial thromboplastin time, prothrombin time and thrombin time.

采用部分凝血活酶时间、凝血酶原时间和凝血酶时间对其体外抗凝血活性作了初步的评价，发现制备的大孔氮化碳对血液不会造成促凝，说明其可能成为一种新的血液相容性材料。

Methods: Human blood samples for platelet function analyzer, aggregometry and blood/HES mixed test were withdrawn into tube containing 3.2% trisodium citrate (blood:citrate 9:1) from an antecubital vein by venipuncture.

由健康捐血者肘静脉抽得的鲜血收集到含抗凝血剂3.2 % trisodium citrate管中，全血与抗凝血剂以9：1 的比例混合，并依照血小板功能分析器、凝集检测仪及羟乙基淀粉与全血混合实验之标准程序备制。

This novel anticoagulative tube has antithrombotic function in the wall.

经凝血时间和凝血因子时间的测定，这种抗凝管具有显著的抗凝血功能，并且管壁上固定着的肝素不脱落。

The split between the two groups can hardly be papered over.

这两个团体间的分歧难以掩饰。

This approach not only encourages a greater number of responses, but minimizes the likelihood of stale groupthink.

这种做法不仅鼓励了更多的反应，而且减少跟风的可能性。